Sandoz Maintains Lead On Denosumab As It Files With FDA

Firm ‘Among The First’ To Submit US Application For Prolia/Xgeva Biosimilar

Sign outside of FDA's headquarters in White Oak, MD
Sandoz’s BLA for denosumab has been accepted by the FDA • Source: Alamy

More from Biosimilars

More from Products